New diabetes drug enters Head-to-Head test against popular treatment
NCT ID NCT07187856
Summary
This study aims to see if a new injectable drug called PG-102 is safe and effective for controlling blood sugar and weight in people with type 2 diabetes. About 80 participants will be randomly assigned to receive PG-102, a placebo (inactive shot), or an open-label drug called semaglutide for 24 weeks. The main goal is to compare how much PG-102 lowers average blood sugar levels compared to the placebo.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS (T2DM) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Emeritus Research
Camberwell, Victoria, 3124, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.